The CSIC has developed a molecule that could potentially be used to treat Parkinson’s disease after having already been tested on mice.
Madrid, Spain, April 15, 2013 – The CSIC has developed a molecule that could potentially be used to treat Parkinson’s disease after having already been tested on mice. The Spanish National Research Council (CSIC) chose World Parkinson’s Day as the occasion to unveil compound S14, a patented molecule that reduces neuronal inflammation and death and acts on the brain’s black matter, which is the area most affected by this disease. The CSIC believes that this substance could be tested in clinical trials on humans within a couple of years.
This discovery was announced during the 11th International Conference on Alzheimer’s and Parkinson’s, which was held recently in Florence. The compound could mitigate the effects of the disease, such as resting tremors, muscular rigidity, cognitive loss, sleep disruption and depression. The development presented by the CSIC, and partially financed by an INNPACTO programme project, would replace treatment of the disease using L-dopa, a substance that can cause involuntary movements after prolonged use.
Telefnica technology in the fight against Parkinson’s
It is not just Spanish science bringing about advances in the treatment of Parkinson’s disease, but Spanish technology too. Telefnica, working with the healthcare consortium Garraf and the Technical University of Catalonia, Barcelona Tech, has launched -Help’, a remote system for treating Parkinson’s patients in real time. This technology, which has already been successfully tested on patients, could be used to administer the medication required based on an individual’s symptoms.
-Help’ improves patients’ quality of life. It is made up of a portable sensor that records the patient’s movements and a pump positioned under the skin to administer the medication. If the sensor detects any deterioration, it notifies the system, which sends instructions to the pump via mobile to increase the dose.
This has already been tested on seven patients in a pilot study, six of whom were Spanish, and who were able to extend time they could spend free of symptoms.
Press Contact: Marca Espana Media Relations Marca Espana Serrano Galvache, 26 28033 Madrid, Espana. 512-212-1139